ImmunityBio (IBRX) Surpasses Enrollment Expectations in QUILT-2.005 Trial, Shares Up 25%
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Source: seekingalpha
- Trial Enrollment Exceeds Expectations: ImmunityBio's QUILT-2.005 trial for BCG-naïve non-muscle-invasive bladder cancer has surpassed 85% enrollment, with full enrollment expected by Q2 2026, accelerating the timeline for the company's biologics license application submission.
- Significant Stock Price Surge: Following the positive enrollment news, ImmunityBio's shares rose 25% in premarket trading to $4.93, building on a 30% gain from the previous session, reflecting strong market confidence in the company's clinical advancements.
- Positive FDA Analysis Results: An interim analysis requested by the FDA demonstrated a statistically significant longer duration of complete response with the ANKTIVA + BCG combination, providing robust support for ImmunityBio's anticipated biologics license application submission by year-end.
- Expanded Access Program Progress: Amid the ongoing TICE BCG shortage, ImmunityBio's Expanded Access Program for recombinant BCG is advancing to support patient access, with the company seeking FDA consultation to explore the use of recombinant BCG as an alternative supply for patients, including those with BCG-naïve disease.
Analyst Views on IBRX
Wall Street analysts forecast IBRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IBRX is 6.33 USD with a low forecast of 5.00 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 3.950
Low
5.00
Averages
6.33
High
8.00
Current: 3.950
Low
5.00
Averages
6.33
High
8.00
About IBRX
Immunitybio, Inc. is a vertically integrated, clinical-stage biotechnology company developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Using its applied science and platforms to treat cancers, including the development of potential cancer vaccines, as well as developing immunotherapies and cell therapies to reduce or eliminate the need for standard high-dose chemotherapy. Its platforms and their associated product candidates are designed to attack cancer and infectious pathogens by activating both the innate immune system, including NK cells, dendritic cells, and macrophages, as well as the adaptive immune system comprising B and T cells, in an orchestrated manner. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins, vaccine vectors, and cell therapies. Its biologic commercial product candidate, Anktiva, is an IL-15 superagonist antibody-cytokine fusion protein.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
